Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Discover a recent study where the authors propose a strategic push to double the diagnostic rate of at-risk MASH by 2030.

Other drugs, including Novo Nordisk's GLP-1 agonist semaglutide, are also in late-stage development for the disease. "Testing new MASH treatments often relies on liver biopsies, where small pieces ...

A survey by PSG has found that the pressure to control drug costs is leading some payers to look into unbundling pharmacy ...

Learn how SGLT2 inhibitor dapagliflozin improves MASH outcomes, with potential clinical use beyond diabetes care.

For patients with MASH, treatment with dapagliflozin is beneficial for improvement of MASH without worsening of fibrosis and for improvement of fibrosis without worsening of MASH.

In that light, the GLP-1 rebound effect is not an obstacle but an opportunity to chart a new, holistic course in obesity care ...

Rybelsus (semaglutide) is a prescription drug that’s used to treat type 2 diabetes. The cost of Rybelsus may depend on factors such as your dosage, whether you have health insurance, and the ...

Ozempic (semaglutide) helps people with type 2 diabetes lower their blood sugar if diet, exercise, and other diabetes medications haven’t worked. If you’ve just gotten a prescription for it ...